Herantis Pharma Announces Poster and Presentation at MDS Virtual Congress 2021
Herantis Pharma Plc, Press Release, 17 September 2021 at 9:00 EEST First-in-Man Clinical Trial of Intraputamenal CDNF in Parkinson’s disease Finds a Consorted Biomarker Response in a Subgroup of Subjects. Herantis Pharma Plc (“Herantis”), focusing on disease modifying therapies for debilitating neurodegenerative diseases, today announced that data highlighting biomarker response in Herantis’ First-in-Man clinical trial of intraputamenal CDNF in Parkinson’s disease will be presented at the International Parkinson and Movement Disorder Society annual congress (MDS Virtual Congress 2021)